Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Zavegepant in Mild Allergic Asthma
NCT04987944Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in allergic asthma comparing Zavegepant with Placebo (2 arms). Primary endpoint: Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge at Day 27. Started Oct 2021; status: terminated.
02
Drugs
zavegepant
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT04987944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987944.